{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:39:48Z","timestamp":1778596788544,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20220401059YY"],"award-info":[{"award-number":["20220401059YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31652-4","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:26:04Z","timestamp":1765441564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants"],"prefix":"10.1038","volume":"15","author":[{"given":"Xue","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weisong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"3","key":"31652_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim, G. E. H. et al. An observational data Meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin. Gastroenterol. Hepatol. 21 (3), 619\u2013629e7. https:\/\/doi.org\/10.1016\/j.cgh.2021.11.038 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"31652_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jhep.2020.07.045","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. & George, J. Reply to: Correspondence regarding A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement: bringing evidence to the NAFLD-MAFLD debate. J. Hepatol. 73 (6), 1575. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.045 (2020).","journal-title":"J. Hepatol."},{"issue":"2","key":"31652_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya, E. & Yilmaz, Y. Metabolic-associated fatty liver disease (MAFLD): A Multi-systemic disease beyond the liver. J. Clin. Transl Hepatol. 10 (2), 329\u2013338. https:\/\/doi.org\/10.14218\/JCTH.2021.00178 (2022).","journal-title":"J. Clin. Transl Hepatol."},{"issue":"14","key":"31652_CR4","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.7150\/ijbs.99176","volume":"20","author":"CY Dai","year":"2024","unstructured":"Dai, C. Y. et al. Reconstruction of the hepatic microenvironment and pathological changes underlying type II diabetes through Single-Cell RNA sequencing. Int. J. Biol. Sci. 20 (14), 5531\u20135547. https:\/\/doi.org\/10.7150\/ijbs.99176 (2024).","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"31652_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.hbpd.2022.01.006","volume":"21","author":"J Zeng","year":"2022","unstructured":"Zeng, J. et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary Pancreat. Dis. Int. 21 (2), 154\u2013161. https:\/\/doi.org\/10.1016\/j.hbpd.2022.01.006 (2022).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"1","key":"31652_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s13679-025-00646-8","volume":"14","author":"MA Farrugia","year":"2025","unstructured":"Farrugia, M. A. et al. Incretins and MAFLD: At the crossroads of endocrine and hepatic disorders. Curr. Obes. Rep. 14 (1), 56. https:\/\/doi.org\/10.1007\/s13679-025-00646-8 (2025). Published 2025 Jun 25.","journal-title":"Curr. Obes. Rep."},{"issue":"3","key":"31652_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4093\/dmj.2023.0350","volume":"48","author":"I Jung","year":"2024","unstructured":"Jung, I., Koo, D. J. & Lee, W. Y. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: Clinical and experimental perspective. Diabetes Metab. J. 48 (3), 327\u2013339. https:\/\/doi.org\/10.4093\/dmj.2023.0350 (2024).","journal-title":"Diabetes Metab. J."},{"issue":"3","key":"31652_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun, D. Q. et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg. Nutr.. 12 (3), 386\u2013403. https:\/\/doi.org\/10.21037\/hbsn-22-421 (2023).","journal-title":"Hepatobiliary Surg. Nutr. Vol"},{"key":"31652_CR9","doi-asserted-by":"publisher","unstructured":"Ohno, R. et al. Oct. Association of metabolic dysfunction-associated fatty liver disease with risk of HF and AF. J. ACC. Asia. https:\/\/doi.org\/10.1016\/j.jacasi.2023.08.003 (2023).","DOI":"10.1016\/j.jacasi.2023.08.003"},{"issue":"Suppl 2","key":"31652_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12072-024-10704-3","volume":"18","author":"Y Fouad","year":"2024","unstructured":"Fouad, Y., Alboraie, M. & Shiha, G. Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatol. Int. 18 (Suppl 2), 827\u2013833. https:\/\/doi.org\/10.1007\/s12072-024-10704-3 (2024).","journal-title":"Hepatol. Int."},{"issue":"1","key":"31652_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12933-022-01518-4","volume":"21","author":"Y Matsubayashi","year":"2022","unstructured":"Matsubayashi, Y. et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc. Diabetol. 21 (1), 90. https:\/\/doi.org\/10.1186\/s12933-022-01518-4 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"31652_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","volume":"122","author":"A Mellemkj\u00e6r","year":"2024","unstructured":"Mellemkj\u00e6r, A., Kj\u00e6r, M. B., Haldrup, D., Gr\u00f8nb\u00e6k, H. & Thomsen, K. L. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur. J. Intern. Med. 122, 28\u201334. https:\/\/doi.org\/10.1016\/j.ejim.2023.11.012 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"31652_CR13","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","volume":"146","author":"P Golabi","year":"2023","unstructured":"Golabi, P. et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the united States. Metabolism 146, 155642. https:\/\/doi.org\/10.1016\/j.metabol.2023.155642 (2023).","journal-title":"Metabolism"},{"key":"31652_CR14","doi-asserted-by":"publisher","unstructured":"Li, T., Wang, Y., Zhao, S., Cui, Y. & Qu, Z. A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients. J. Diabetes Investig.  https:\/\/doi.org\/10.1111\/jdi.70112 (2025).","DOI":"10.1111\/jdi.70112"},{"key":"31652_CR15","doi-asserted-by":"publisher","unstructured":"Cui, Y., Qu, Z., Li, L. & Hu, W. Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes. BMC Gastroenterol. 25 (1), 322. https:\/\/doi.org\/10.1186\/s12876-025-03917-9  (2025).","DOI":"10.1186\/s12876-025-03917-9"},{"issue":"Suppl","key":"31652_CR16","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31 (Suppl), S32\u2013S50. https:\/\/doi.org\/10.3350\/cmh.2024.0431 (2025).","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"31652_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-Year cohort study in China. J. Clin. Endocrinol. Metab. 107 (1), 88\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgab641 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"31652_CR18","doi-asserted-by":"publisher","unstructured":"Han, E. et al. Association of temporal MAFLD with type 2 diabetes, cardiovascular disease and mortality. Cardiovasc Diabetol. 24 (1), 289. https:\/\/doi.org\/10.1186\/s12933-025-02824-3 (2025).","DOI":"10.1186\/s12933-025-02824-3"},{"issue":"8","key":"31652_CR19","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"Y Sakurai","year":"2021","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T. & Kadowaki, T. Role of insulin resistance in MAFLD. Int. J. Mol. Sci. 22 (8), 4156. https:\/\/doi.org\/10.3390\/ijms22084156 (2021). Published 2021 Apr 16.","journal-title":"Int. J. Mol. Sci."},{"key":"31652_CR20","doi-asserted-by":"publisher","first-page":"1515797","DOI":"10.3389\/fpubh.2025.1515797","volume":"13","author":"X Huang","year":"2025","unstructured":"Huang, X., Wu, Y., Ni, Y., Xu, H. & He, Y. Global, regional, and National burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front. Public. Health. 13, 1515797. https:\/\/doi.org\/10.3389\/fpubh.2025.1515797 (2025). Published 2025 Jan 23.","journal-title":"Front. Public. Health"},{"issue":"4","key":"31652_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00592-023-02209-6","volume":"61","author":"F Folli","year":"2024","unstructured":"Folli, F. et al. Alanine transferase levels (ALT) and triglyceride-glucose index are risk factors for type 2 diabetes mellitus in obese patients. Acta Diabetol. 61 (4), 435\u2013440. https:\/\/doi.org\/10.1007\/s00592-023-02209-6 (2024).","journal-title":"Acta Diabetol."},{"issue":"9","key":"31652_CR22","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1507\/endocrj.EJ20-0794","volume":"68","author":"SN Li","year":"2021","unstructured":"Li, S. N. et al. Association between blood Urea nitrogen and incidence of type 2 diabetes mellitus in a Chinese population: a cohort study. Endocr. J. 68 (9), 1057\u20131065. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0794 (2021).","journal-title":"Endocr. J."},{"key":"31652_CR23","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.2147\/IJGM.S327841","volume":"14","author":"C Wu","year":"2021","unstructured":"Wu, C., Ma, D. & Chen, Y. Association of pulse pressure difference and diabetes mellitus in Chinese people: A cohort study. Int. J. Gen. Med. 14, 6601\u20136608. https:\/\/doi.org\/10.2147\/IJGM.S327841 (2021). Published 2021 Oct 11.","journal-title":"Int. J. Gen. Med."},{"issue":"2","key":"31652_CR24","doi-asserted-by":"publisher","first-page":"100892","DOI":"10.1016\/j.aohep.2022.100892","volume":"28","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. Ann. Hepatol. 28 (2), 100892. https:\/\/doi.org\/10.1016\/j.aohep.2022.100892 (2023).","journal-title":"Ann. Hepatol."},{"issue":"10","key":"31652_CR25","doi-asserted-by":"publisher","first-page":"e41778","DOI":"10.1097\/MD.0000000000041778","volume":"104","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Impact of hemoglobin level on the association between lipid metabolism and gestational diabetes mellitus: A retrospective study. Med. (Baltim). 104 (10), e41778. https:\/\/doi.org\/10.1097\/MD.0000000000041778 (2025).","journal-title":"Med. (Baltim)."},{"issue":"4","key":"31652_CR26","doi-asserted-by":"publisher","first-page":"EVIDoa2400229","DOI":"10.1056\/EVIDoa2400229","volume":"4","author":"Z Yao","year":"2025","unstructured":"Yao, Z. et al. Associations between class I, II, or III obesity and health outcomes. NEJM Evid. 4 (4), EVIDoa2400229. https:\/\/doi.org\/10.1056\/EVIDoa2400229 (2025).","journal-title":"NEJM Evid."},{"issue":"8","key":"31652_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7326\/ANNALS-24-02547","volume":"178","author":"D Dicker","year":"2025","unstructured":"Dicker, D., Karpati, T., Promislow, S. & Reges, O. Implications of the European association for the study of obesity\u2019s new framework definition of obesity: Prevalence and association with All-Cause mortality. Ann. Intern. Med. 178 (8), 1065\u20131072. https:\/\/doi.org\/10.7326\/ANNALS-24-02547 (2025).","journal-title":"Ann. Intern. Med."},{"key":"31652_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.02.003","author":"NWS Chew","year":"2023","unstructured":"Chew, N. W. S. et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell. Metab. ;35(3):414\u2013428e3. doi:https:\/\/doi.org\/10.1016\/j.cmet.2023.02.003 (2023)."},{"key":"31652_CR29","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism 160, 155999. https:\/\/doi.org\/10.1016\/j.metabol.2024.155999 (2024).","journal-title":"Metabolism"},{"issue":"25","key":"31652_CR30","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.3748\/wjg.v30.i25.3132","volume":"30","author":"D Wang","year":"2024","unstructured":"Wang, D., Zhou, B. Y., Xiang, L., Chen, X. Y. & Feng, J. X. Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease. World J. Gastroenterol. 30 (25), 3132\u20133139. https:\/\/doi.org\/10.3748\/wjg.v30.i25.3132 (2024).","journal-title":"World J. Gastroenterol."},{"key":"31652_CR31","doi-asserted-by":"publisher","first-page":"1626203","DOI":"10.3389\/fendo.2025.1626203","volume":"16","author":"S Bao","year":"2025","unstructured":"Bao, S., Jin, Q., Wang, T., Mao, Y. & Huang, G. Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population. Front. Endocrinol. (Lausanne). 16, 1626203. https:\/\/doi.org\/10.3389\/fendo.2025.1626203 (2025). Published 2025 Jul 11.","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"31652_CR32","doi-asserted-by":"publisher","first-page":"1521168","DOI":"10.3389\/fendo.2025.1521168","volume":"16","author":"Y Cui","year":"2025","unstructured":"Cui, Y. et al. A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients. Front. Endocrinol. (Lausanne). 16, 1521168. https:\/\/doi.org\/10.3389\/fendo.2025.1521168 (2025). Published 2025 May 29.","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"31652_CR33","doi-asserted-by":"publisher","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","volume":"14","author":"H Peng","year":"2023","unstructured":"Peng, H. et al. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. Adults. Front. Endocrinol. (Lausanne). 14, 1083032. https:\/\/doi.org\/10.3389\/fendo.2023.1083032 (2023). Published 2023 Jan 19.","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"31652_CR34","doi-asserted-by":"publisher","first-page":"e004514","DOI":"10.1136\/bmjdrc-2024-004514","volume":"12","author":"X Lei","year":"2024","unstructured":"Lei, X. et al. Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus. BMJ Open. Diabetes Res. Care. 12 (5), e004514. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004514 (2024). Published 2024 Sep 25.","journal-title":"BMJ Open. Diabetes Res. Care"},{"issue":"36","key":"31652_CR35","doi-asserted-by":"publisher","first-page":"e39437","DOI":"10.1097\/MD.0000000000039437","volume":"103","author":"B Yang","year":"2024","unstructured":"Yang, B. & Zhong, X. Clinical model to predict the risk of nonalcoholic fatty liver disease: A secondary analysis of data from a cross-sectional study. Med. (Baltim). 103 (36), e39437. https:\/\/doi.org\/10.1097\/MD.0000000000039437 (2024).","journal-title":"Med. (Baltim)."},{"issue":"Suppl 4(Suppl 4","key":"31652_CR36","doi-asserted-by":"publisher","first-page":"e13256","DOI":"10.1111\/obr.13256","volume":"22","author":"A Bellicha","year":"2021","unstructured":"Bellicha, A. et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. Obes. Rev. 22 (Suppl 4(Suppl 4), e13256. https:\/\/doi.org\/10.1111\/obr.13256 (2021).","journal-title":"Obes. Rev."},{"issue":"12","key":"31652_CR37","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/2047487320908983","volume":"28","author":"P Dikaiou","year":"2021","unstructured":"Dikaiou, P. et al. Obesity, overweight and risk for cardiovascular disease and mortality in young women. Eur. J. Prev. Cardiol. 28 (12), 1351\u20131359. https:\/\/doi.org\/10.1177\/2047487320908983 (2021).","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31652-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31652-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:22:36Z","timestamp":1765815756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31652-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["31652"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31652-4","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.cmet.2023.02.003","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the Ethics Committee of the Affiliated Hospital of Changchun University of Traditional Chinese Medicine (Approval Number: CCZYFYLL-SQ-2025\u5ba1\u5b57-252), and complies with the provisions of the Helsinki Declaration. This project is a retrospective study and does not involve any intervention on the subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43855"}}